Kachemov Marketta, Vaibhav Vineet, Smith Charlene, Sundararaman Niveda, Heath Marie, Pendlebury Devon F, Matlock Andrea, Lau Alice, Morozko Eva, Lim Ryan G, Reidling Jack, Steffan Joan S, Van Eyk Jennifer E, Thompson Leslie M
Neurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
Advanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Brain. 2025 Apr 3;148(4):1212-1227. doi: 10.1093/brain/awae319.
Huntington's disease is a neurodegenerative disorder caused by an expanded CAG repeat mutation in the Huntingtin (HTT) gene. The mutation impacts neuronal protein homeostasis and cortical/striatal circuitry. SUMOylation is a post-translational modification with broad cellular effects including via modification of synaptic proteins. Here, we used an optimized SUMO protein-enrichment and mass spectrometry method to identify the protein SUMOylation/SUMO interaction proteome in the context of Huntington's disease using R6/2 transgenic and non-transgenic mice. Significant changes in the enrichment of SUMOylated and SUMO-interacting proteins were observed, including those involved in presynaptic function, cytomatrix at the active zone, cytoskeleton organization and glutamatergic signalling. Mitochondrial and RNA-binding proteins also showed altered enrichment. Modified SUMO-associated pathways in Huntington's disease tissue include clathrin-mediated endocytosis signalling, synaptogenesis signalling, synaptic long-term potentiation and SNARE signalling. To evaluate how modulation of SUMOylation might influence functional measures of neuronal activity in Huntington's disease cells in vitro, we used primary neuronal cultures from R6/2 and non-transgenic mice. A receptor internalization assay for the metabotropic glutamate receptor 7 (mGLUR7), a SUMO-enriched protein in the mass spectrometry, showed decreased internalization in R6/2 neurons compared to non-transgenic neurons. SiRNA-mediated knockdown of the E3 SUMO ligase protein inhibitor of activated STAT1 (Pias1), which can SUMO modify mGLUR7, reduced this Huntington's disease phenotype. In addition, microelectrode array analysis of primary neuronal cultures indicated early hyperactivity in Huntington's disease cells, while later time points demonstrated deficits in several measurements of neuronal activity within cortical neurons. Huntington's disease phenotypes were rescued at selected time points following knockdown of Pias1. Collectively, our results provide a mouse brain SUMOome resource and show that significant alterations occur within the post-translational landscape of SUMO-protein interactions of synaptic proteins in Huntington's disease mice, suggesting that targeting of synaptic SUMO networks may provide a proteostatic systems-based therapeutic approach for Huntington's disease and other neurological disorders.
亨廷顿舞蹈症是一种神经退行性疾病,由亨廷顿(HTT)基因中CAG重复序列的扩增突变引起。该突变影响神经元蛋白质稳态和皮质/纹状体神经回路。SUMO化是一种翻译后修饰,具有广泛的细胞效应,包括通过修饰突触蛋白产生的效应。在这里,我们使用优化的SUMO蛋白富集和质谱方法,利用R6/2转基因小鼠和非转基因小鼠,在亨廷顿舞蹈症背景下鉴定蛋白质SUMO化/SUMO相互作用蛋白质组。观察到SUMO化和SUMO相互作用蛋白的富集有显著变化,包括那些参与突触前功能、活性区细胞基质、细胞骨架组织和谷氨酸能信号传导的蛋白。线粒体蛋白和RNA结合蛋白的富集也发生了改变。亨廷顿舞蹈症组织中SUMO相关的修饰途径包括网格蛋白介导的内吞信号传导、突触形成信号传导、突触长期增强和SNARE信号传导。为了评估SUMO化的调节如何影响体外培养的亨廷顿舞蹈症细胞中神经元活动的功能指标,我们使用了来自R6/2小鼠和非转基因小鼠的原代神经元培养物。对代谢型谷氨酸受体7(mGLUR7,一种质谱分析中富含SUMO的蛋白)进行的受体内化测定显示,与非转基因神经元相比,R6/2神经元的内化减少。RNA干扰介导的E3 SUMO连接酶蛋白——激活的信号转导和转录激活因子1(STAT1)的蛋白抑制剂(Pias1)的敲低,可对mGLUR7进行SUMO修饰,减轻了这种亨廷顿舞蹈症表型。此外,对原代神经元培养物进行的微电极阵列分析表明,亨廷顿舞蹈症细胞早期存在活动亢进,而在后期时间点,皮质神经元的多项神经元活动测量显示存在缺陷。在敲低Pias1后的选定时间点,亨廷顿舞蹈症表型得到了挽救。总的来说,我们的研究结果提供了一种小鼠脑SUMO组资源,并表明在亨廷顿舞蹈症小鼠中,突触蛋白的SUMO蛋白相互作用的翻译后格局发生了显著改变,这表明靶向突触SUMO网络可能为亨廷顿舞蹈症和其他神经疾病提供一种基于蛋白质稳态系统的治疗方法。